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1410Objective: Warfarin reduces risk of stroke in patients with mechanical heart valves but increases risk of hem-
orrhage and is difficult to use. Dabigatran etexilate, a new oral direct thrombin inhibitor, is safe and effective in
reducing risk of stroke among patients with atrial fibrillation. No data exist in the setting of mechanical heart
valves. We tested the hypothesis that dabigatran etexilate is as effective as heparin for thromboprophylaxis of
mechanical valves in a porcine heterotopic aortic valve model.
Methods: Thirty swine underwent implantation of modified bileaflet mechanical valved conduit bypassing the
ligated, native descending thoracic aorta. Animals randomly received no anticoagulation (n ¼ 10), enoxaparin
2 mg/kg subcutaneously twice daily (n ¼ 10), or dabigatran etexilate 20 mg/kg orally twice daily. Primary end
point was amount of valve thrombus at 30 days. Secondary end points included quantitative measurement of
platelet deposition on valve prosthesis, thromboelastography, and hemorrhagic and embolic events.
Results: At 30 days, we observed 638  895 mg thrombus in no anticoagulation group, 121  128 mg in enox-
aparin group, and 19 31 mg in dabigatran etexilate group (P¼ .01 enoxaparin vs dabigatran etexilate). Fewer
platelets were deposited on valves in dabigatran etexilate group (2.73 108) than in enoxaparin group (1.83 109,
P¼ .03). No major or occult hemorrhagic or embolic events were observed. By thromboelastographic analysis,
dabigatran etexilate produced less prolongation of K value (P ¼ .01) and less decreases in angle (P ¼ .01) and
maximum amplitude (P ¼ .001) than enoxaparin.
Conclusions: Dabigatran etexilate is as effective as enoxaparin for short-term thromboprophylaxis of mechan-
ical valves. It prevents valve thrombus and platelet deposition at 30 days without increased adverse events. These
promising results serve as a foundation for prospective clinical trials with dabigatran etexilate as an alternative to
warfarin in patients with bileaflet mechanical aortic valves. (J Thorac Cardiovasc Surg 2011;141:1410-6)There is increasing interest in using new anticoagulation
strategies for patients with mechanical heart valves because
of the hemorrhagic and thromboembolic complications as-
sociated with long-term anticoagulation with warfarin.1
Several new classes of medications have been developed
for long-term anticoagulation2,3 and have been studied
clinically for conditions such as atrial fibrillation4,5 and
prevention and treatment of deep venous thrombosis after
orthopedic surgery.6,7
Dabigatran etexilate is a novel, orally administered direct
thrombin inhibitor that has proved safe and effective for
treating deep venous thrombosis8 and preventing stroke in
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ical valve prostheses. Unlike warfarin, dabigatran etexilate
has a rapid clinical onset with a predictable dose response.
Additionally, there are no known food or drug interactions,
and it does not require frequent monitoring for therapeutic
effect. Its half-life is approximately 12 hours, and other
than the active form (dabigatran), the drug does not have ac-
tive metabolites and is eliminated through renal and intesti-
nal routes.
We hypothesized that dabigatran etexilate would provide
equal thromboprophylaxis of mechanical heart valves as
standard anticoagulation strategies. We tested this hypothe-
sis in porcine model of heterotopically placed mechanical
aortic valves.MATERIALS AND METHODS
Animal Model
Approval for this study was obtained from the animal care and use com-
mittee of the Mayo Foundation. Adult swine underwent heterotopic me-
chanical aortic valve placement as previously reported.9 The model uses
a modified bileaflet aortic valved conduit (St Jude Masters Series; St
Jude Medical, Inc, Minneapolis, Minn), which bypasses the ligated, native
descending thoracic aorta and directs all blood flow distal to the left subcla-
vian artery across the mechanical valve in the newly constructed neoaorta
(Figure 1).gery c June 2011
Abbreviation and Acronym
APTT ¼ activated partial thromboplastin time
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Dosing study. Dabigatran etexilate is a novel, orally administered pro-
drug of the direct thrombin inhibitor dabigatran. Unlike warfarin, it has
a rapid clinical onset with a predictable dose response. Additionally, there
are no known food or drug interactions, and it does not require frequent
monitoring for therapeutic effect. Its half-life is approximately 12 hours,
and it has no other active metabolites. Dabigatran is predominantly elimi-
nated by renal excretion.10
To identify the most effective doses of dabigatran etexilate and enoxa-
parin in swine, we first performed a dosing study. Animals were dosed with
either dabigatran etexilate or enoxaparin, and appropriate hematologic as-
say samples were drawn at 0, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, and 72 hours.11
Our aim was to find the doses of dabigatran etexilate and enoxaparin that
corresponded to therapeutic levels in our strain of animals. For dabigatran
etexilate, we aimed to increase the activated partial thromboplastin time
(APTT) 2 to 2.5 times normal. For enoxaparin, we sought an anti-Xa level
of at least 0.6 at 4 hours.12
In vivo thromboprophylaxis of mechanical valves. Spe-
cific details regarding this model of heterotopic aortic valve prostheses
have been reported elsewhere.9,13 Briefly, 30 swine were randomly
sorted into 3 treatment arms of postoperative anticoagulation. These
treatments consisted of no anticoagulation (n ¼ 10), enoxaparin (Sanofi
Aventis US, Bridgewater, NJ) at 2.0 mg/kg administered subcutaneously
twice daily (n ¼ 10), and dabigatran etexilate at 20 mg/kg by mouth
twice daily (n ¼ 10). The clinical formulation of dabigatran etexilate
(small tartaric acid pellets coated with drug in capsules) was used in theFIGURE 1. Heterotopic aortic valve model demonstrating the modified
valved conduit (St Jude Masters Series; St Jude Medical, Inc, Minneapolis,
Minn) as it bypasses the ligated native descending thoracic aorta (used with
permission from Mayo Foundation for Medical Education and Research).
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Germany). The low–molecular weight heparin enoxaparin was used as
the standard for anticoagulation because of the difficulty in maintaining
a therapeutic window with warfarin in swine.14 Additionally, low–
molecular weight heparins are used to bridge patients to warfarin anticoa-
gulation and as an alternative to warfarin for some patients unable to take
warfarin.15,16 These doses were determined from the results of our dosing
studies. Animals received their assigned treatment medication beginning
on postoperative day 1.
End Points
Valve thrombus. The primary end point of this study was the amount
of valve thrombus at 30 days.16 Animals were killed while under general
anesthesia after systemic heparinization, at which time valve thrombus
was measured and reported as mean  SD in milligrams. Only thrombus
on the valve was measured, and this was done by investigators blinded to
the treatment arm (S.H.M.).
Platelet deposition. We measured the amount of platelet deposition
on the valve prostheses as another quantitativemethod of assessing thrombus
burden and effects of different anticoagulation regimens. Platelet deposition
on the mechanical prosthesis in the chronic study was assessed with autolo-
gous platelet labeling with indium 111 as previously described.13,17,18 After
explantation but before quantitation of thrombus burden, the valve was
placed into a scintillation radiocounter (Capintec, Inc, Ramsay, NJ).
Background radioactivity and the amount of radioactivity from 2 10-mL
tubes of blood was obtained when each animal was killed. By assessing
the animal’s platelet count and radioactivity obtained from the tubes of
blood, the average amount of radioactivity per platelet was determined.
This was used to calculate the number of platelets on the prosthesis
according to the following equation: Number of platelets on valve
prosthesis ¼ Valve radioactivity/Platelet radioactivity.
Hemorrhagic and thromboembolic complications. Sec-
ondary end points were obvious or occult hemorrhagic and thromboem-
bolic complications. Animals were observed daily for hemorrhagic
complications (obvious gastrointestinal hemorrhage) and for thromboem-
bolic complications (neurologic deficits or lower extremity or bowel ische-
mia). Additionally, kidneys were grossly and microscopically inspected
when each animal was killed to search for gross and microembolic events.
Occult hemorrhagewas sought for as animals underwent serial blood draws
to measure serum and fecal hemoglobin concentrations. Occult hemor-
rhagic events were defined as a drop in serum hemoglobin of at least
2 m/dL or an abnormally high fecal hemoglobin level (>2 mg hemoglo-
bin/g of stool).
Coagulation profile. We used several hematologic and anticoagula-
tion assays to assess the effects of dabigatran etexilate on the coagulation
system. At baseline (before valve implantation), on days 10 and 20, and
when the animal was killed (30 days), we performed a complete blood
cell count; measured prothrombin time, APTT, fibrinogen, and anti-Xa
levels; and performed thromboelastography. We used the TEG 5000 de-
vice with native and kaolin cups and pins (Haemoscope Corporation,
Niles, Ill). Measurements obtained included R time (minutes), K time
(minutes), angle (degrees), and maximal amplitude (mm). R time mea-
sures time to initial fibrin formation, K time measures time to strong
clot formation and cross-linking, angle measures the speed of clot
strengthening, and maximum amplitude measures final clot strength. We
included thromboelastography because it evaluates the entire coagulation
system and is becoming more widely used in managing cardiovascular
surgical patients.Statistical Analysis
Valve thrombus and number of platelets deposited on valve prosthesis
are reported as mean  SD in milligrams and were treated as continuous
variables and compared with the Kruskal–Wallis test for heterogeneity.diovascular Surgery c Volume 141, Number 6 1411
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Dosing Study
Administration of dabigatran etexilate at 20 mg/kg orally
twice daily reproducibly increased the APTT to 2 to 2.5
times normal (Figure 2, A). Administration of enoxaparin
at 2.0 mg/kg subcutaneously twice daily reproducibly
increased anti-Xa levels to at least 0.6 (Figure 2, B). These
doses were used for the remainder of the study.10
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Serial hematologic assays confirmed appropriate dose
and drug effects for both treatment arms. The APTT in-
creased in animals treated with dabigatran etexilate, and
there was also a significant increase in the prothrombin
time. (Figure 3, A and B). As expected, we observed
increased anti-Xa levels at all time points for animals
receiving enoxaparin relative to the no anticoagulation
and dabigatran etexilate groups (Figure 3, C). We ob-
served significantly less circulating fibrinogen in the dabi-
gatran etexilate group at all 3 time points of the study
(Figure 3, D).250 
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FIGURE 2. Results of dosing study for enoxaparin and dabigatran etexi-
late for 3 animals. A, For dabigatran etexilate, the goal was an activated
partial thromboplastin time (APTT) of 60 seconds (2–2.5 times normal).
B, The goal for enoxaparin was an anti-Xa level of 0.6 at 4 hours after
dosing.
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FIGURE 3. Coagulation values throughout study for each group. A,Mean
activated partial thromboplastin time (aPTT). B, Mean prothrombin time
(PT). C, Mean anti-Xa. D, Mean fibrinogen. No AC, No anticoagulation;
LMWH, low–molecular weight heparin; Dabig, dabigatran etexilate.
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There was 1 premature death in the no anticoagulation
group as a result of overwhelming sepsis on postoperative
day 6. When the animals were killed, mean thrombus
weight was statistically different between the groups. We
observed 638  895 mg of thrombus with no anticoagula-
tion, 121  128 mg with enoxaparin, and 19  31 mg
with dabigatran etexilate (P¼ .04; Figure 4, A). This repre-
sented a 30-fold decrease in mean valve thrombus for the
dabigatran etexilate group relative to the no anticoagulation
group. Comparing the 2 treatment groups, we found signif-
icantly less thrombus on valves among animals receiving
dabigatran etexilate (P ¼ .02; Figure 4, B). Similarly, the
mean number of platelets deposited on the valve prosthesis
was lower in the dabigatran etexilate group (2.73 108) than
in the enoxaparin group (1.8 3 109, (P ¼ .03; Figure 4, C).P 0= . 20
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FIGURE 4. A, Mean valve thrombus in milligrams ( SEM) for each
group at 30 days. B, Mean valve thrombus for the 2 treatment arms at
30 days (P ¼ .03), demonstrating that the animals that received dabigatran
etexilate had the least valve thrombus development. C, Mean platelet depo-
sition on valves for the 2 treatment arms. No AC, No anticoagulation.
FIGURE 5. Postmortem photographs of explanted valves at 30 days. A,
Representative valve from the no anticoagulation group. B, Representative
valve from the enoxaparin group. C, Representative valve from the dabiga-
tran etexilate group.
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FIGURE 6. Thromboelastographic data for the 3 groups. A, Mean R time
(minutes), representing rate of initial fibrin formation. B, Mean K time
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DRepresentative postmortem photographs of explanted
valves from the no anticoagulation, enoxaparin, and dabiga-
tran etexilate groups are shown in Figure 5.
Thrombotic and Hemorrhagic Complications
There were no obvious hemorrhagic or thromboembolic
complications. Similarly, there was no evidence of occult
bleeding in any of the groups according to serum or fecal
hemoglobin assays.
Thromboelastography
Native and kaolin thromboelastographic assays were per-
formed at baseline and during anticoagulation.We observed
that at least in vivo the thromboelastographic coagulation
profile (R and K times, angle, and maximum amplitude)
in animals receiving dabigatran etexilate looked more like
the profiles obtained from animals with no anticoagulation
than like those of animals receiving enoxaparin (Figure 6).
This was true for both kaolin and native thromboelasto-
graphic assays (native data not shown), suggesting adequate
anticoagulation despite a normal-appearing thromboelasto-
graphic profile.
DISCUSSION
The principal finding of this study is that the novel direct
thrombin inhibitor dabigatran etexilate is effective for
thromboprophylaxis of mechanical heart valves in swine.
This is the first application of dabigatran etexilate for anti-
coagulation of mechanical heart valves. In this short-term
animal study, treatment with dabigatran etexilate was supe-
rior to anticoagulation with heparin and led to the lowest
amounts of valve thrombus and platelet deposition at
30 days.
The concept of dabigatran etexilate as a replacement for
warfarin for long-term anticoagulation in patients with me-
chanical valves is promising. Recent clinical trials evaluat-
ing dabigatran etexilate for venous thromboembolism and
atrial fibrillation showed equivalent or superior efficacy
with similar safety profiles. Connolly and colleagues5 dem-
onstrated equivalent rates of thromboembolic and hemor-
rhagic events relative to warfarin for patients with chronic
atrial fibrillation.5 Similarly, Schulman and associates8 re-
ported equivalent safety and efficacy to warfarin in prevent-
ing recurrent deep venous thrombosis after orthopedic joint
replacement. Similar results were observed for prevention
of primary deep venous thrombosis relative to low–molec-
ular weight heparin after orthopedic surgery.19,20 If theinutes), representing time to strong clot formation and cross-linking.
Mean angle (degrees), representing speed of clot strengthening. D,
ean maximum amplitude (millimeters), representing final clot strength.
, Not significant; No AC, no anticoagulation; LMWH, low–molecular
eight heparin; Dabig, dabigatran etexilate.
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Dpattern of safety and efficacy of dabigatran etexilate can be
extended to patients with mechanical valve prostheses, this
would represent a major step forward in clinical care.
Unlike warfarin, dabigatran etexilate has rapid in vivo ac-
tivation and no known drug or food interactions. It has
a rapid onset of 2 to 3 hours after ingestion and has
a half-life of about 15 hours. It is given twice daily for
chronic conditions and does not require invasive blood
monitoring as does warfarin.21 In addition, the liver toxicity
reported for earlier direct thrombin inhibitors has not been
observed in these clinical trials. Dabigatran etexilate carries
many advantages relative to warfarin: it has no food or drug
interactions, does not require routine blood testing, and has
a short half-life. It could thus dramatically improve the
quality of life in patients who need long-term anticoagula-
tion and could prove safer should emergency surgery be
needed. Dabigatran etexilate, like any new drug, requires
further studies to determine the best indications for patients
with mechanical valves. Whether direct thrombin inhibitors
can replace warfarin in selected patients undergoing long-
term anticoagulation or whether its use is best reserved
for bridging patients to anticoagulation with warfarin needs
to be tested in clinical trials.
The thromboelastographic data were unexpected, be-
cause animals receiving dabigatran etexilate had the least
amount of thrombus and platelet deposition but the throm-
boelastographic profile more closely resembled that of
animals receiving no anticoagulation (Figure 6). Specifi-
cally, the times to fibrin and clot formation (R and K
times) and the measurements of clot strength (angle and
maximal amplitude) were nearly identical to those in con-
trol animals. This paradoxic observation suggests ex vivo
preservation of the hemostatic axis cascade while provid-
ing excellent anticoagulation in vivo. Additionally, we
found that prothrombin time had better correlation than
APTT to the degree of valve thrombus at 30 days. This
is in contrast to results of different assays with human
plasma, in which the prothrombin time was quite insensi-
tive to dabigatran etexilate.18 To our knowledge, this is the
first time that dabigatran etexilate has been evaluated in
swine and evaluated with thromboelastography. Our unex-
pected observations warrant further investigation and may
reflect species variation or assay sensitivity to a new class
of anticoagulant agents. We were also intrigued by the
decreased levels of circulating fibrinogen in dabigatran
etexilate–treated animals at all points during the study
(Figure 3, D). This may have contributed to less valve
thrombus formation because less fibrinogen was available
for fibrin formation. This finding also requires further
study.
The primary limitation of this study lies in the compari-
son between dabigatran etexilate and enoxaparin rather
than warfarin, which is used clinically. This was necessary,
because anticoagulating swine with warfarin has provedThe Journal of Thoracic and Carextremely difficult.14 We are reassured, however, by how
reproducible this model has been now that we have used
it to study various anticoagulation strategies.11,13
CONCLUSIONS
The novel direct thrombin inhibitor dabigatran etexilate
was effective for short-term thromboprophylaxis of me-
chanical heart valves in our porcine model. These animal
data provide additional support for clinical trials evaluating
dabigatran etexilate as an alternative to warfarin for appro-
priately selected patients with bileaflet mechanical valve
aortic valves.
We thank Joseph A. Rysavy, BS, for his expertise with animal
care and DeAnna Haugen for her assistance with thromboelastog-
raphy. We also thank St Jude Medical for providing the valved
conduits for this study.
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Dr Y. Joseph Woo (Philadelphia, Pa). That was very nice talk.
Do the valve leaflets move in your model?
Dr McKellar. In this model, they do not. We have verified that
under fluoroscopy, and a main reason that we chose this model
rather than an intracardiac model is because at 30 days it was
much more robust in thrombus formation.
Dr Woo. So have you not created a model system that is exag-
gerating the thrombus generation? Isn’t the relative amount of de-
crease in thrombus formation in your experimental group always
going to look better because your control group is so bad? Most
valves in human beings when placed into a native position would
not generate that much clot.
Dr McKellar. Correct, and that is why we choose this valve.
When we were developing this model, one of our first studies
was to compare this with an orthotopic mitral valve position with-
out any anticoagulation, and we found a lot less thrombus in the
orthotopic position. We therefore chose the heterotopic position,
because the pig grows so rapidly and at 30 days we can keep the
pig at minimum growth. So in a short time we can develop a lot
of thrombus. I do accept the criticism that this may not completely
represent reality of the mechanical valve.
Dr Woo. I just think that it limits the conclusions that you can
draw.
Dr McKellar. Thank you for your question.
DrMichael E. Jessen (Dallas, Texas). I enjoyed your talk, and I
really hope that this works out, because I think there is potential in
this for patients. One of the difficulties I have with this, though, is
that you measured the intensity of anticoagulation in the 2 treat-
ment groups by different methods. One was by anti–factor Xa ac-
tivity and one was by partial thromboplastin time. So because you
were not using exactly the same targets, is it possible that the dif-
ference just represents an intensity of anticoagulation, a higher
dose of anticoagulation if you like, in one group, and not so
much an effect specific to the drug itself?1416 The Journal of Thoracic and Cardiovascular SurDr McKellar. It could, and thank you for your question. This
is in large part why we wanted to do a more global evaluation of
clot function or clot strength with thromboelastography. Accord-
ing to what is out there in the literature, the anti-Xa levels are
fairly well established for the low–molecular weight heparins,
whereas for the dabigatran etexilate group it is a little less clear.
The best evidence out there for readily available tests for direct
thrombin inhibitors is an APPT of 2 to 2.5 times normal, but I
understand what you are saying. And we thought that we would
see perhaps something like that in the thromboelastographic
data, but in fact we saw the reverse. We saw what appears in vi-
tro to be preserved clot function by thromboelastography with
dabigatran etexilate versus enoxaparin. As for the anti-Xa level
of 0.6, were we overly anticoagulating in either arm? What we
saw on valve thrombus was different from what we saw on
thromboelastography, leaving the question open. A good ques-
tion. Thank you.
Dr Carlos J. Troconis (Santiago, Dominican Republic). There
have been several studies in Europe and South Africa about se-
lected cases of On-X valves in aortic replacement without the
use of warfarin anticoagulation, treating them only with antiplate-
let therapy to avoid thromboembolic events. Do you have any com-
ments about this?
Dr McKellar.We have used this model to look at dual antipla-
telet therapy with aspirin and clopidogrel. I know that others
around the world have published results of that in human beings.
I think that the best place to study that is in patients with good
left ventricular function and high flow across a mechanical aortic
valve. I know that the On-X people are kind of leading the way in
doing some of those trials. But havewe done that in human beings?
If that is your question, no, we haven’t. I do hope that our and other
data would push the community toward clinical trials to try this
agent in human beings.
Dr Glen Van Arsdell (Toronto, Ontario, Canada). Pigs are no-
toriously hard to anticoagulate. With unfractionated heparin, you
have to give enormous doses. I have 2 questions in that regard.
One is the timing of measuring your anti-Xa values. Are you really
satisfied that the low–molecular weight heparin was anticoagulat-
ing the whole time? The second thing is, if you look at the data on
mechanical valves in pregnancy (a hypercoagulable state), low–
molecular weight heparin is not as effective as you would like it
to be in terms of preventing valve thrombosis. Does low–molecu-
lar weight heparin really anticoagulate well enough in the face of
a potentially hypercoagulable physiology?
Dr McKellar. Thank you for your question. According to the
American College of Chest Physicians guidelines for deep vein
thrombosis and pulmonary embolism prophylaxis or treatment,
the best data they have is an anti-Xa of 0.6 at 4 hours after admin-
istration, and that is what we duplicated in this study. As towhether
there are subtle nuances between the species, granted, I don’t have
that perfect answer.
Dr. Van Arsdell. So you didn’t measure anti-Xa levels right be-
fore giving your second dose?
DrMcKellar. Before we did any of the valve implantations, we
did a dosing study to find the exact right dose of dabigatran etex-
ilate for our species, as well as the correct dose of enoxaparin, and
we did several different doses. The dose we chose consistently
yielded a value of 0.6 at 4 hours.gery c June 2011
